¡Ya estamos en ! Descubre más

NovoCure

NVCR

Capitalización de mercado USD 1638 M

14.07 USD

-0.34

2.36%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

14.07

0.00

0%

1 día

-2.36%

5 días

-3.23%

1 mes

-13.26%

3 meses

-14.31%

6 meses

11.49%

En lo que va del año

7.24%

1 año

0.29%

5 años

-87.25%

10 años

92.21%

Acerca de: NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Empleados: 1,605

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 54.5%

Neutral 40.9%

Negativo 4.5%

Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.

Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. “The approval of Optune Pax provides a promising new treatment option for locally advanced pancreatic cancer, a disease with an urgent need for effective therapies,” said Makoto Ueno, MD, PhD, D.

Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

Novocure to Report Third Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 29, to discuss the company's financial results for the three-month period that ended September 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided.

Novocure to Report Third Quarter 2026 Financial Results

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research

Novocure Reports Patient Data Exposure in Cybersecurity Incident

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

Novocure Reports Patient Data Exposure in Cybersecurity Incident

Novocure Announces Upcoming Investor Events

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with investors. Morgan Stanley 24th Annual Global Healthcare Conference, September 14, 2026: Mr. Leonard and Christoph Brackmann, Chief Financial Officer, will take par.

Novocure Announces Upcoming Investor Events

Oncology firm Novocure says cyberattack exposed US patient records

Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed ‌internal records of more than 1,400 U.S. patients.

Oncology firm Novocure says cyberattack exposed US patient records

Zacks Investment Research

Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™